非布索坦
医学
痛风
别嘌呤醇
卡那努马布
高尿酸血症
重症监护医学
内科学
尿酸
阿纳基纳
疾病
作者
Lisa K. Stamp,Nicola Dalbeth
标识
DOI:10.1038/s41584-018-0149-7
摘要
In 2018, advances in the treatment of gout flares came in the form of a new nurse-led management approach to serum urate lowering and evidence that allopurinol might have a better cardiovascular safety profile than febuxostat. However, are IL-1β blockers such as canakinumab the future of care for patients with gout?
科研通智能强力驱动
Strongly Powered by AbleSci AI